Brilacidin's Phase II clinical trial for COVID-19 is scheduled to begin next week

Clinical biopharmaceutical company Innovation Pharmaceuticals recently announced that its Phase II clinical trial for Brilacidin, which treats COVID-19, is scheduled to begin next week.
Phase II randomized, placebo-controlled clinical trials will recruit approximately 120 moderate to severe COVID-19 hospitalized patients who were randomly assigned to the Brilacidin treatment group and the placebo control group, with approximately 60 patients in each group.
The main endpoint of the trial was the 29th day of continuous recovery based on the American Institute of Allergy and Infectious Diseases (NIAID), and other endpoints included in-hospital prognosmation, all-cause mortality, determination of inflammatory-related biomarkers, and changes in SARS-CoV-2 viral load.
the company believes Brilacidin has great prospects to help address the COVID-19 global pandemic.
brilacidin's antiviral mechanism is to attack coronavirus directly by destroying the integrity of the virus membrane.
suggests that Brilacidin can still attack the virus even if it mutates.
company looks forward to starting its clinical trials to further assess Brilacidin's COVID-19 therapeutic potential.